Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Chystáte se opustit lokální stránky Czech Proto budete přesměrování na celosvětové stránky, které jsou dostupné?
Nezobrazujte znovu tuto zprávu
Ano
Ne

Vyhledávali jste podle

Hledali jste

Relevantní informace

Důležité kontakty

Připravované akce

Příbuzné produkty

Farmaceutika, všeobecně a speciální - Kalifornie

Nejdůležitější body

Výzkum a studie
Organizace
Upřesněte, prosím, svou studii podle segmentu trhu, aby bylo možno získat odpovídající ratingy a monitorované údaje.
  DatumTyp dokumentu Název Emitent/entita
22 Apr 2024 Rating Action Moody's Ratings affirms Bausch Health's Caa2 CFR; revises outlook to stable Bausch + Lomb C...
Bausch + Lomb E...
Bausch Health A...
Bausch Health C...
02 Apr 2024 Peer Snapshot Gilead Sciences, Inc. - December 2023 (LTM): Peer Snapshot Gilead Sciences, Inc.
27 Mar 2024 Rating Action Moody's affirms Cencora's Baa2 senior unsecured rating, outlook revised to positive AmeriSource Hea...
Bergen Brunswig...
Bergen Brunswig...
Bergen Capital ...
Bergen Capital ...
Bergen Capital ...
Cencora, Inc.
Durr-Fillauer M...
PharMerica, Inc...
27 Mar 2024 Rating Action Moody's upgrades McKesson's senior unsecured rating to A3, outlook stable California Gold...
General Medical...
McKesson Canada...
McKesson Corpor...
McKesson Financ...
McKesson Financ...
Mckesson Financ...
Mckesson Financ...
Mckesson Financ...
18 Mar 2024 Peer Snapshot Amgen Inc. - December 2023 (LTM): Peer Snapshot Amgen Inc.
14 Mar 2024 Credit Opinion Amgen Inc.: Near-term focus on pipeline execution, integration of Horizon Therapeutics and deleveraging Amgen Inc.
13 Mar 2024 Announcement of Periodic Review Moody's announces completion of a periodic review of ratings of Amgen Inc. Amgen Inc.
12 Mar 2024 Announcement of Periodic Review Moody's announces completion of a periodic review of ratings of MI OpCo Holdings, Inc. MI OpCo Holdings, Inc.
12 Feb 2024 Announcement Moody's says Gilead's acquisition of CymaBay will enhance liver product portfolio and growth prospects Gilead Sciences, Inc.
12 Feb 2024 Issuer Comment Gilead Sciences, Inc.: Acquisition of CymaBay will enhance liver product portfolio and growth prospects Gilead Sciences, Inc.
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry